戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              HPN costs were euro13,276 for treatment introduction, fo
2                                              HPN imaging may provide a new method for detection of pr
3                                              HPN patients were evaluated after a mean period of 5.1 y
4                                              HPN-targeted imaging agents were synthesized by conjugat
5 was estimated that in 1992 there were 40,000 HPN patients and 152,000 HEN patients nationwide.
6 were compared among 10 ITx recipients and 10 HPN patients.
7 ificance (p < 5 x 10(-8)) for serum albumin (HPN-SCN1B, GCKR-FNDC4, SERPINF2-WDR81, TNFRSF11A-ZCCHC2,
8 me UFC1, which presents a TAK rather than an HPN motif.
9 -saving for patients with end-stage CIPO and HPN-associated complications.
10 A-seq analysis of transcriptomes from HP and HPN primary melanomas identified a 32-gene signature (HP
11                          Two loci, SOCS3 and HPN, each harbor 2 conditionally distinct, noncoding var
12                       The mean +/- SD age at HPN onset was 0.7 +/- 0.3 y, with a mean duration of 1.9
13  who may benefit from transplantation before HPN-associated secondary organ failure.
14 quality of life was markedly similar between HPN-dependent patients and ITx recipients, with signific
15 hough an asparagine residue in the conserved HPN motif of E2 enzymes was suggested to stabilize the o
16                                      Daytime HPN was feasible and safe in adults with SBS and, compar
17 lable diarrhea or ostomy output with daytime HPN.
18  including surgery, admissions, diagnostics, HPN therapy, medication, and ambulatory care were includ
19             SBS was the major indication for HPN in our cohort.
20                          The indications for HPN were divided into primary digestive diseases (PDDs)
21                          The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), c
22 ing was associated with a poorer outcome for HPN patients, it was still reasonably good; therefore, a
23    Whole-genome sequencing of melanomas from HPN mice revealed a striking increase in lung metastatic
24 ve identified a pair of robust marker genes (HPN and STAT6) by integrating microarray datasets from t
25 e Nme1 and Nme2 metastasis suppressor genes (HPN mice).
26                                    Geriatric HPN patients had a generally good outcome but did not do
27 7) for delays in mental development; Hepsin (HPN) for ID and Collagen Type VI Alpha 3 Chain (COL6A3),
28 ys have resulted in the discovery of hepsin (HPN) as a biomarker for detection of prostate cancer.
29 eneficial for successful catheter salvage in HPN-dependent patients with a CRBSI.
30 life in ITx recipients is similar to that in HPN-dependent patients.
31  of the composite FOLE was well tolerated in HPN-dependent children.
32 IH4 levels with viral control; and increased HPN, PRKCB, and ITGB3 levels with increased risk of dise
33             We used phage display to isolate HPN binding peptides with 190 + 2.2 nmol/L affinity in m
34 ost strongly associated serum albumin locus, HPN, for which Hpn knockout mice manifest low plasma alb
35 absorption, which is associated with a lower HPN dependence.
36 sulfate sodium-induced mouse colitis models, HPN-NE-EcN showed substantially enhanced prophylactic an
37   When injected into mouse xenograft models, HPN-targeted nanoparticles bound specifically to HPN-exp
38                        Correspondingly, most HPNs showed strong dendritic labeling for both GluR1 and
39  and developed ROS-scavenging nanoparticles (HPN) that could effectively scavenge ROS.
40 ved that treatment of human primary neurons (HPNs) with methamphetamine and HIV gp120 and Tat increas
41 d cultures of hippocampal pyramidal neurons (HPNs) exposed to low pH (acidosis).
42 ) channels on hippocampal pyramidal neurons (HPNs) has been controversial, although they are present
43 xpressing LNCaP xenografts compared with non-HPN-expressing PC3 xenografts.
44                   Home parenteral nutrition (HPN) and intestinal transplantation (ITx) are the 2 trea
45 SBS) dependent on home parenteral nutrition (HPN) commonly cycle infusions overnight, likely contribu
46 nt absorption and home parenteral nutrition (HPN) dependence in SBS patients with intestinal failure.
47 e indications for home parenteral nutrition (HPN) in children and describe the outcome over a 14-y pe
48 dren on long-term home parenteral nutrition (HPN) receiving a composite fish oil-based emulsion (FOLE
49 eness compared to home parenteral nutrition (HPN) therapy in chronic intestinal failure are lacking.
50 failure receiving home parenteral nutrition (HPN) to that among patients who underwent intestinal tra
51 stage disease and home parenteral nutrition (HPN)-associated complications.
52 and dependency on home parenteral nutrition (HPN).
53 es in patients on home parenteral nutrition (HPN).
54                   The major complications of HPN were catheter-related bloodstream infections (CRBSIs
55 In this study, we explore the development of HPN imaging probes for detection of prostate cancer.
56 safety, and efficacy of daytime infusions of HPN in adults with SBS without diabetes.
57 ber 2013, 52% of children were weaned off of HPN, 9% of the PDD subgroup had intestinal transplantati
58 ion, characterization, and photochemistry of HPN. and HNP. in N(2)-matrix at 3 K.
59 ning 10 recipients required reinstitution of HPN due to allograft enterectomy (n = 3) or gut dysfunct
60                 In contrast, the majority of HPNs (putatively identified by morphological criteria an
61                           A subpopulation of HPNs, however, displayed noticeable [Ca2+]i rises that b
62 erved in SBS children 6 mo after weaning off HPN.
63                            The dependence on HPN was expressed by the number of infusions per week an
64 enty patients with CD and IF, established on HPN, were evaluated for ITx.
65 adults with SBS and, compared with overnight HPN, improved subjective sleep without increasing 24-h g
66 mg/dL lower with daytime than with overnight HPN.
67 ) min lower with daytime than with overnight HPN.
68 e was lower with daytime than with overnight HPN.
69 hout IR, all patients progressed to home PN (HPN).
70 licited Th1 dominant immunity in mice; PSMA, HPN, and AMACR.
71  All patients suffered gut failure, received HPN, and experienced life-threatening complications.
72 cenarios, a proportion of patients receiving HPN were eventually eligible for an intestinal transplan
73 r institution and discharged while receiving HPN between 1 January 2000 and 31 December 2013.
74 nsduction case-studies, including the recent HPN-DREAM breast cancer challenge.
75            Silencing of three representative HPN lung metastasis signature genes (ARRDC3, NYNRIN, RND
76 ry melanomas identified a 32-gene signature (HPN lung metastasis signature) for which decreased expre
77 plest derivatives of PN, the radical species HPN. and HNP. have remained elusive.
78                                Specifically, HPN. was formed as a weakly bonded complex with CO in th
79 hronic intestinal failure, 28 adults, stable HPN patients were studied.
80                                    In stable HPN patients, the costs were 83 402 ( 35 364-169 146) in
81 nce of Ca-A/K channels and further show that HPNs display considerable heterogeneity in terms of appa
82 uate our algorithm on simulated data and the HPN-DREAM pathway reconstruction challenge, comparing ou
83                         Here we describe the HPN-DREAM network inference challenge, which focused on
84  achieve colon tissue targeting effects, the HPN nanoparticles were conjugated to the surface of modi
85 e art represented by the methods used in the HPN-DREAM challenge.
86              One-quarter to one-third of the HPN group was aged > or = 65 y, depending on the underly
87                                     In these HPNs, levels of GluR1 relative to GluR2 were higher, and
88 ery expensive, is cost-effective compared to HPN in adults by year 4, and cost-saving by year 5.
89  and evaluate cost-effectiveness compared to HPN.
90 targeted nanoparticles bound specifically to HPN-expressing LNCaP xenografts compared with non-HPN-ex
91 rreversible IF and both of these treatments--HPN and ITx--to estimate the cost-effectiveness of ITx.
92 hed and life-threatening complications under HPN were unresolvable.
93 compared with 684 +/- 541; P < 0.05), as was HPN dependence (33% +/- 20% compared with 48% +/- 38%; P
94 vival of patients with IF in comparison with HPN at an additional cost of euro19,529 per life-year ga
95 ith <12 mo of remaining life expectancy with HPN if they did not undergo ITx.
96 crobiota were increased after treatment with HPN-NE-EcN, contributing to the alleviation of IBDs.